Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination and the treatment of colorectal cancer.
October 31 2023 - 8:18AM
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S)
receives a notification from the EPO regarding the “Intention to
Grant” for patents of the subsidiary's wound-healing drug
combination and the treatment of colorectal cancer.
October 31, 2023
Company Announcement No. 42
Pharma Equity Group's subsidiary
(Reponex Pharmaceuticals A/S) receives a notification from the
European Patent Office (EPO) regarding the issuance of a patent for
the subsidiary's wound-healing drug combination (RXN-022) and the
company's treatment for colorectal cancer.
Reponex Pharmaceuticals A/S (Reponex) announced
today that the EPO has issued an "Intention To Grant" for EU patent
applications numbers 15724673.7 and 19701467.3.
The former application, which pertains to the
wound-healing candidate RNX-022, describes a method for treating
chronic wounds by applying a hydrogel containing
granulocyte-macrophage colony-stimulating factor (GM-CSF),
sucralfate, and hyaluronan to accelerate wound healing.
The latter application concerns the colorectal
cancer candidate RNX-051 and describes a method for suppressing
bacterial layers (biofilms) protecting the cancerous tumor or
adenomas (potential tumors) from the body's immune system in the
colon or rectum.
A Notice of “Intention to Grant" indicates that
the EPO intends to issue the patents after certain standard
procedural steps are completed, with the patents expected to be
granted within 2 months, valid until 2035 and 2039,
respectively.
"It is with great joy, that we today received
the European Patent Office's notification of their 'intention to
grant' for Reponex's treatment of venous leg ulcers. This decision
strengthens our belief in the product's significance and the
innovative potential it represents.
But it doesn't stop there; Reponex has also
concurrently obtained 'intention to grant' for our treatment
method, which combines two specific antibiotics aimed at
selectively combating the bacteria that protect cancerous tumors in
the colon and rectum from the body's immune system. This is a
significant step forward in our efforts to contribute to cancer
treatment and provide hope for those battling this dreadful
disease.
We are deeply grateful for EPO's recognition and
look forward to continuing our work to make these treatments
accessible to those who need them most," says Thomas Kaas Selsø,
CEO of Pharma Equity Group A/S.
According to Grand View Research, the global
wound care market was valued at USD 21.4 billion in 2022 and is
expected to grow at a compound annual growth rate (CAGR) of 4.15%
from 2023 to 2030.
According to the World Health Organization (WHO)
and The International Agency for Research on Cancer (IARC), the
global colorectal cancer market was valued at USD 9.4 billion in
2020. Each year, approximately 57 million new cases of adenomas and
about 1.5 million new cases of colorectal cancer are reported in
Western countries.
For further information, please
contact: Thomas Kaas Selsø, CEO Phone: +45 4022 2114
Email: tks@pharmaequitygroup.com
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring the
utmost success and impact of Reponex Pharmaceuticals' medical
projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2023-10-31 - Announcement no 42 - UK
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jul 2023 to Jul 2024